Abstract
Objective To evaluate the expression of NJ001 specific antigen in lung adenocarcinoma,and the relationship between the antigen and clinicopathological features. Methods A case-control study was conducted.Tumor tissues of 113 lung adenocarcinoma and 46 benign lung disease were collected from the First Affiliated Hospital of Nanjing Medical University.The expression of NJ001 specific antigen was examined by means of immunohistochemistry,and the results were scored by semiquantitative analysis.Then the associations of the antigen expression with several clinicopathologic features and the potential value in prognosis were assessed.Statistical analysis was evaluated by chi-square test or Fisher exact test. Results The positive rate of NJ001 specific antigen was 84.70% in 113 lung adenocarcinoma,which was higher than 8.70% in benign lung disease,and there were significant differences between the two groups (χ2=79.050,P<0.01).In lung adenocarcinoma of poor and moderate differentiation,the positive rate of NJ001 specific antigen was 89.41%,and it was significantly higher than 63.16% in well differentiation patients (P=0.009); Meanwhile,the positive rate in patients with lymph nodes metastasis was 91.53%,which was markedly higher than 75.51% in those without lymph nodes metastasis (χ2=5.177,P<0.05). Kaplan-Meier survival analysis showed that the higher level of the specific antigen patients expressed,the lower survival rate they acquired.Cox proportional hazards model revealed that high expression of NJ001 specific antigen was an independent risk factor for post-operation overall survival of lung adenocarcinoma patients. Conclusions The expression of NJ001 specific antigen is closely correlated with tumor differentiation degree and lymph node metastasis in lung adenocarcinoma patients,and it promises to be a novel marker for prognosis of lung adenocarcinoma patients.(Chin J Lab Med,2013,36:895-898) Key words: Lung neoplasms; Adenocarcinoma; Antibodies; monoclonal; Immunohistochemistry
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
